Marty Makary resigned as the commissioner of the Food and Drug Administration (FDA) amid reports of internal policy disagreements, particularly over the approval of flavored e-cigarettes. His departure follows tension within the FDA, highlighted by the approval of fruit-flavored vapes from Glas Inc., which Makary reportedly opposed but was pressured to approve by the Trump administration. President Trump, who had reportedly planned to fire Makary, praised him as a “great guy” but acknowledged his difficulties in the role. Makary’s resignation is part of broader upheaval within the Department of Health and Human Services, with other key figures like vaccines chief Vinay Prasad also leaving. The FDA, a crucial agency regulating drugs, vaccines, and tobacco, has faced significant challenges, including political appointees taking over leadership roles traditionally held by career officials. Dr. Scott Gottlieb, a former FDA commissioner, noted that these changes have taken a toll on the agency’s effectiveness. Kyle Diamantas is expected to step in as acting commissioner and testify in Makary’s place on Capitol Hill.
QUESTION: How might the frequent changes in leadership at the FDA impact public trust in the agency’s decisions and policies?
Marty Makary resigns as FDA commissioner after internal tensions
